Ammonium and chronic liver diseases — the inseparable tandem | Український Медичний Часопис

Chronic liver diseases occupy one of the leading places among digestive diseases, the course of which in most cases in the initial stages is subclinical, which leads to late coming patients to hospitals and, as a result, the disease progression and the development of liver cirrhosis. The key cells of the liver responsible for the extracellular matrix deposition in response to hepatocellular damage are hepatic stellate cells. According to in vivo and in vitro studies the action of them is activated under the ammonium influence. According to the literature data, in chronic liver diseases, ammonium excretion decreases due to the implementation of the ornithine cycle of urea synthesis (the main path of ammonium detoxification), and the removal of ammonium by muscles increases. Some authors provide data that removing excess ammonium concentration can restore the function of hepatic stellate cells, which indicates the reversibility of the process. A well-known drug that effectively reduces the level of toxic ammonium is original L-ornithine L-aspartate, which prevents hyperammonemia by increasing the synthesis of urea, which indicates the possibility of using the drug in the treatment of chronic liver diseases. Although this drug has already proven himself well in the treatment of liver cirrhosis, hepatic encephalopathy, and liver failure, today its effect on the course of non-alcoholic fatty liver disease is being actively studied.

References

1. Харченко Н.В. (2016) Хронічні захворювання печінки: гепатопротекторна фармакотерапія в умовах реальної клінічної практики. Сучасна гастроентерологія, 6: 70–75.
2. Величко В.І., Колотвіна Л.І., Гур’єв А.М. та ін. (2014) Ожиріння й неалкогольна жирова хвороба печінки з позиції кардіоваскулярного ризику в практиці сімейного лікаря. Медицина транспорту України, 1: 79–82.
3. Lombardo Y.B., Hein G., Chicco A. (2007) Metabolic syndrome: effects of n-3 PUFAs on a model of dyslipidemia, insulin resistance and adiposity. Lipids, 42: 427–437.
4. Sorrentino P., Tarantino G., Conca P. et al. (2004) Silent non-alcoholic fatty liver disease-a clinical-histological study. J. Hepatol., 41(5): 751–757. DOI: 10.1016/j.jhep.2004.07.010.
5. Perseghin G., Bonfanti R., Magni S. et al. (2006) Insulin resistance and whole body energy homeostasis in obese adolescents with fatty liver disease. Am. J. Physiol. Endocrinol. Metab., 291: 697–703.
6. Shoelson S.E., Lee J., Goldfine A.B. (2006) Inflammation and insulin resistance. J. Clin. Invest., 116: 1793–1801.
7. Sreenivasa B.C., Alexander G., Kalyani B. et al. (2006) Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol., 21: 191–198.
8. Stefan N., Machicao F., Staiger H. et al. (2005) Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia, 48: 2282–2291.
9. Arab J.P., Arrese M., Trauner M. (2018) Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annual Review of Pathology: Mechanisms of Disease, 13: 321–350.
10. Thomsen K.L., De Chiara F., Rombouts K. et al. (2018) Ammonia: A novel target for the treatment of non-alcoholic steatohepatitis. Med. Hypotheses, 113: 91–97. DOI: 10.1016/j.mehy.2018.02.010.
11. Jalan R., De Chiara F., Balasubramaniyan V. et al. (2016) Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension. J. Hepatol., 64: 823–833.
12. Gutiérrez-de-Juan V., López de Davalillo S., Fernández-Ramos D. et al. (2017) A morphological method for ammonia detection in liver. PLoS One, 12: e0173914.
13. Wei Y., Rector R.S., Thyfault J.P., Ibdah J.A. (2008) Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J. Gastroenterol., 14: 193–199.
14. De Chiara F., Thomsen K.L., Habtesion A. et al. (2020) Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease. Hepatology, 71(3): 874–892. DOI: 10.1002/hep.30890.
15. Butterworth R.F., Canbay A. (2018) Hepatoprotection by L-ornithine L-aspartate in non-alcoholic fatty liver disease. Dig. Dis. Basel. Switz., 17: 1–6.
16. Grüngreiff K., Lambert-Baumann J. (2001) Efficacy of L-ornithin-L-aspartate-granules in chronic liver diseases. Medizinische Welt-stuttgart, 52(7): 219–226.
17. Tian L., Lu L., Tang C. et al. (2013) Aspartate-ornithine granules in the treatment of nonalcoholic steatohepatitis: a multiple-dose parallel controlled clinical trial. Zhonghua Gan Zang Bing Za Zhi Zhonghua Ganzangbing Zazhi Chin. J. Hepatol., 21: 528–532.
18. Ermolova T., Ermolov S. (2018) Correction of intrahepatic microcirculation disorders by L-ornithine-L-aspartate at the chronic liver diseases patients. J. Hepatol., 68: 585–586.